ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
| Revenue (TTM) | $1.10B |
| Gross Profit (TTM) | $674.45M |
| EBITDA | $92.71M |
| Operating Margin | -1.72% |
| Return on Equity | 37.30% |
| Return on Assets | 3.69% |
| Revenue/Share (TTM) | $6.47 |
| Book Value | $7.29 |
| Price-to-Book | 2.90 |
| Price-to-Sales (TTM) | 3.30 |
| EV/Revenue | 2.568 |
| EV/EBITDA | 30.34 |
| Quarterly Earnings Growth (YoY) | -81.80% |
| Quarterly Revenue Growth (YoY) | 9.70% |
| Shares Outstanding | $171.24M |
| Float | $127.25M |
| % Insiders | 0.33% |
| % Institutions | 99.08% |
Volatility is currently contracting